ADVERTISEMENTs
.png)
India's life sciences innovation ecosystem sees remarkable progress: Karun Rishi
USAIC on April 21, unveiled the full program agenda for its highly anticipated 18th annual BioPharma & Healthcare Summit
In this file picture, USAIC president Karun Rishi addressing 13th India US Health Care summit in 2019 / USAIC
There has been remarkable progress in India's life sciences innovation ecosystem, the head of a top Indian pharma centric business chambers has said ahead of the 18th edition of the annual USA India Chamber of Commerce (USAIC) in Boston on April 25.
“Over the past 18 years, USAIC has engaged extensively with top global BioPharma leaders and investors, witnessing remarkable progress in India's life sciences innovation ecosystem,” said USAIC president Karun Rishi in a statement on April 21.
“This growth is further propelled by pragmatic supportive policies implemented by the Indian government, positioning India as a strategic partner for the US and other Western countries in the BioPharma domain. Despite the current global geopolitical and economic challenges, India remains a beacon of hope, poised to continue its upward trajectory for the foreseeable future,” he said.
Based out of Boston, USAIC on April 21, unveiled the full program agenda for its highly anticipated 18th annual BioPharma & Healthcare Summit.
The participation of top US government official Dr. Robert Califf, US FDA Commissioner, underscores the keen interest and commitment of the US FDA to collaborate closely with India, strengthening regulatory frameworks and ensuring the production of high-quality medicines in the country, he said.
“Dr. Califf will share insights from his significant visit to India last September, which holds paramount importance for both nations,” Rishi said.
Prominent speakers at the day-long summit including Biogen CEO Chris Viehbacher, R&D heads like Andrew Plump of Takeda, Marcus Schindler of Novo Nordisk, Robert Plenge of BMS, and academic leaders Marc Tessier-Lavigne of Stanford and George Daley of Harvard Medical School.
The summit will also witness active participation from leading investors such as Noubar Afeyan of Flagship Pioneering, along with senior leaders from Fidelity Investments, Google Ventures, TVM Capital Healthcare Partners, Abingworth, SV Health Investors, and other prominent companies, highlighting the keen interest of global biopharma investors and companies to collaborate and invest in India.
Notable figures from the Indian pharma industry, including Dilip Shanghvi of Sun Pharma and Hari Bhartia of Jubilant Bhartia Group, will participate in the summit, further enriching the discourse and fostering meaningful partnerships.
By partnering with international stakeholders, India can accelerate its journey towards becoming a global hub for BioPharma innovation, while also contributing to the advancement of global health outcomes. “Ultimately, by embracing a collaborative approach to medical innovation, we can unlock new possibilities, break down barriers, and create a healthier and more prosperous future for people around the globe,” Rishi said.
“Indian government’s innovation-driven top leadership, coupled with India’s substantial skilled manpower, positions the country as a trusted Partner of Choice for BioPharma research and development, clinical research, and manufacturing. With its ability to scale up manufacturing capacity while maintaining high-quality standards, India is primed to play a pivotal role in producing life-saving medicines for global consumption, addressing critical concerns regarding BioPharma supply chain and health security,” Rishi said.
ADVERTISEMENT
ADVERTISEMENT
E Paper
Video
.png)
.png)
.png)
.jpeg)
.jpg)
.jpg)
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login